Evidence map›Paper›PMID 40033382›Full record

Observational studyMalaria journal2025

An observational pilot study of an active surveillance tool to enhance pharmacovigilance in Brazil.

Dhelio Batista Pereira, Marcus Vinícius Guimarães Lacerda, Pavandeep Bilkhu, Carolina Duarte, Ioana-Gabriela Fiţa, Felix Jackson, Siôn Jones, Ana Martin, Marcia Rangel, Katie Rolfe and 3 more

Abstract readObservational Study
In one paragraph

Observational study in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dhelio Batista PereiraCentro de Pesquisa em Medicina Tropical de Rondônia, Porto Velho, Rondônia, Brazil.ORCID http://orcid.org/0000-0002-7761-5498
Marcus Vinícius Guimarães LacerdaFundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.ORCID http://orcid.org/0000-0003-3374-9985
Pavandeep BilkhumedDigital, London, UK.ORCID http://orcid.org/0009-0000-6452-7977
Carolina DuartemedDigital, London, UK.ORCID http://orcid.org/0009-0003-1977-8410
Ioana-Gabriela FiţaGSK, London, UK.ORCID http://orcid.org/0009-0000-1872-5278
Felix JacksonmedDigital, London, UK.ORCID http://orcid.org/0009-0001-3066-2406
Marcia RangelGSK, Rio de Janeiro, Brazil. marcia.h.rangel@gsk.com.ORCID http://orcid.org/0009-0004-3789-7920
Katie RolfeGSK, Stevenage, UK.ORCID http://orcid.org/0000-0002-8635-4891
Alex TeckkammedDigital, London, UK.ORCID http://orcid.org/0009-0007-7450-7719
Roberto ZajdenvergGSK, Rio de Janeiro, Brazil.ORCID http://orcid.org/0009-0000-8117-9185
Anup PingleGSK, Mumbai, India. anup.s.pingle@gsk.com.ORCID http://orcid.org/0000-0002-9844-7323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActive surveillance involves systematically monitoring patients to seek detailed information about the occurrence of adverse events (AEs) following drug administration. The Seta technology was developed to improve active surveillance of AEs or pregnancy in low- and middle-income countries and geographically challenging areas. Seta actively solicits responses from participants via WhatsApp messages. The study aimed to determine whether Seta facilitated reporting of AEs and pregnancies to the Brazilian National Health Surveillance Agency (ANVISA).

methodsMalaria patients participating in the Tafenoquine Roll-out STudy (TRuST) in Brazil's Amazon region were invited to participate in this observational pilot study evaluating Seta. The study was conducted at two sites from 27 July 2022 to 28 October 2022. Seta sent messages to all participants on Day 7 and in Week 8 asking if they had experienced an AE or if they had become pregnant during the time since they took the malaria medication. If a participant responded "yes", a pharmacovigilance coordinator (PVC) called them to collect further details, which the PVC was then encouraged to report to ANVISA.

resultsThis pilot study included 149 participants, 50 from Manaus and 99 from Porto Velho. On Day 7, 117 (79%) of 149 participants responded to WhatsApp messages generated by Seta asking whether they had experienced an AE or become pregnant; 45 participants responded "yes". At Week 8, 64 (55%) of the Day 7 responders also responded, 10 of whom indicated that they had experienced an AE or become pregnant. A total of 55 follow-up calls were therefore attempted by PVCs, of which, 25 (45%) were answered and allowed for reporting of AEs and pregnancies, as appropriate, to ANVISA.

conclusionsThis observational pilot study provides insights into how digital reporting tools such as Seta can enhance pharmacovigilance in remote areas and build upon existing signal detection methodologies. Twenty-five AEs or pregnancies were reported to ANVISA that were unlikely to have been reported otherwise.

Indexed as

Adverse Drug Reaction Reporting SystemsAntimalarialsMalariaPharmacovigilanceAdolescentAdultBrazilDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiddle AgedPilot ProjectsPregnancyYoung AdultAntimalarialsActive surveillanceAdverse eventBrazilMalariaPharmacovigilanceTafenoquineTechnologyWhatsApp

Identifiers

PMID40033382
PMCPMC11877895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.